Investigators Present Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML at the 2022 American Society of Hematology Annual Meeting

December 13, 2022

https://www.globenewswire.com/news-release/2022/12/13/2572708/0/en/Investigators-Present-Clinical-Data-on-Salarius-Pharmaceuticals-Seclidemstat-in-Patients-with-MDS-and-CMML-at-the-2022-American-Society-of-Hematology-Annual-Meeting.html

Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine

50% overall response rate among eight myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who relapsed or progressed after hypomethylating agent therapy

Read more at globenewswire.com

Related news for (SLRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.